Treatment of Tuberculosis

Sarah Tapyrik, MD

Sept 26, 2018

The Ohio State University
Wexner Medical Center

Slides curtesy of Chris Vinnard, MD
Rutgers, Global Tuberculosis Institute

The Ohio State University
Wexner Medical Center

Outline

- Principles of treatment of tuberculosis
- Recommended treatment regimens
- Case management and monitoring
- Special circumstances

Treatment of Tuberculosis, 1940's



Saskatchewan Lung Association

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

Payam Nahid,[1] Susan E. Dorman,[2] Narges Alipanah,[1] Pennan M. Barry,[3] Jan L. Brozek,[4] Adithya Cattamanchi,[1] Lelia H. Chaisson,[1] Richard E. Chaisson,[2] Charles L. Daley,[5] Malgosia Grzemska,[6] Julie M. Higashi,[7] Christine S. Ho,[8] Philip C. Hopewell,[1] Salmaan A. Keshavjee,[9] Christian Lienhardt,[6] Richard Menzies,[10] Cynthia Merrifield,[1] Masahiro Narita,[12] Rick O'Brien,[13] Charles A. Peloquin,[14] Ann Raftery,[1] Jussi Saukkonen,[15] H. Simon Schaaf,[16] Giovanni Sotgiu,[17] Jeffrey R. Starke,[18] Giovanni Battista Migliori,[11] and Andrew Vernon[8]

[1]University of California, San Francisco; [2]Johns Hopkins University, Baltimore, Maryland; [3]California Department of Public Health, Richmond; [4]McMaster University, Hamilton, Ontario, Canada; [5]National Jewish Health, Denver, Colorado; [6]World Health Organization, Geneva, Switzerland; [7]Tuberculosis Control Section, San Francisco Department of Public Health, California; [8]Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; [9]Harvard Medical School, Boston, Massachusetts; [10]McGill University, Montreal, Quebec, Canada; [11]WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri Care and Research Institute, Tradate, Italy; [12]Tuberculosis Control Program, Seattle and King County Public Health, and University of Washington, Seattle; [13]Ethics Advisory Group, International Union Against TB and Lung Disease, Paris, France; [14]University of Florida, Gainesville; [15]Boston University, Massachusetts; [16]Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa; [17]University of Sassari, Italy; and [18]Baylor College of Medicine, Houston, Texas

Replaces CDC: *Treatment of Tuberculosis*, MMWR. June 20, 2003 / Vol. 52 / No. RR-11

* Clin Infect Dis, 2016:63 (1 October) • e147
https://www.cdc.gov/tb/publications/guidelines/pdf/cid_ciw694_full.pdf

Treatment of TB: Objectives

- The treatment of TB is centered on curing the individual patient and decreasing the transmission of TB bacteria to other people
- The objectives of TB therapy are:
  - Cure the individual patient and minimize risk of death and disability
  - Reduce transmission of *M. tuberculosis* to other persons
  - Prevent the development of drug resistance during therapy

ATS/IDSA/CDC 2016 Treatment Guidelines

"Evidence-based" Guidelines* for the Treatment of Tuberculosis

Strength of the recommendation

A. Preferred; should generally be offered
B. Alternative; acceptable to offer
C. Offer when *A* or *B* regimens cannot be given
D. Should generally not be offered
E. Should never be offered

Quality of evidence supporting the recommendation

I. At least 1 randomized trial with clinical endpoints
II. Clinical trials that were not randomized or were performed in other populations
III. Expert opinion

* IDSA/USPHS

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Key Considerations

- Recommendation 1: Patient-centered approach
  - Endorses the use of case management
    - Conditional recommendation; very low certainty of evidence
- Recommendation 2: DOT for all forms of TB disease
  - Conditional recommendation; very low certainty in the evidence

CDC 2016

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Goals of Anti-tuberculosis Chemotherapy

- Rapid killing of tubercle bacilli
- Minimize potential for organisms to develop drug resistance: Combination chemotherapy
- Sterilize host tissues: Sufficient length of treatment
- Result: Patient is cured with very small likelihood of relapse

Initiation of Therapy

- Often is based on high index of suspicion
  - Do not delay treatment waiting for smear and culture results, especially in ill and vulnerable patients
  - Absence of AFB on smear or granulomas on biopsy does not rule out tuberculosis, nor does negative TB culture
  - A positive TST or IGRA is only supportive, may be negative in 15-25% of cases



Clin Infect Dis, 2016:63 (1 October) • e147

The Ohio State University Wexner Medical Center

Drugs in Current Use

First-line	Second-line	xxx-line
Isoniazid (INH)	Cycloserine	Linezolid*
Ethambutol (EMB)	Levofloxacin*	Bedaquiline
Rifampin (RIF)	Ethionamide	
Rifabutin* (RBT)	Moxifloxacin*	
Rifapentine (RPT)	*p*-Aminosalicylic acid (PAS)	
Pyrazinamide (PZA)	Capreomycin	
Streptomycin (SM)	Gatifloxacin*	
	Amikacin/Kanamycin*	

** Not approved by FDA for use in tuberculosis*

2017

The Ohio State University Wexner Medical Center

Bedaquiline (TMC 207)

- Accelerated FDA approval, November 2012
  - 2 studies involving a total of 440 patients with MDR-TB: Time to culture conversion
  - Safety concerns
- Unique mechanism
  - ATP synthase proton pump inhibitor
- Indication
  - As part of combination therapy for the treatment of MDR pulmonary TB in adults
- Phase 3 trial
  - Double-blind study: 9 months bedaquiline *versus* placebo, with background regimen

Sirturo® Janssen Therapeutics

The Ohio State University Wexner Medical Center

Treatment of Culture-positive Pulmonary Tuberculosis

General Conclusions from the Literature

- 6 months (26 wks) is the minimum duration of treatment
- 6 month regimens require a rifamycin throughout and PZA for the first 2 months
- 6 month regimens are effective without INH

The Ohio State University Wexner Medical Center

Treatment of Culture-positive Pulmonary Tuberculosis

General Conclusions from the Literature

- Without PZA minimum duration is 9 months (39 wks)
- Without RIF, minimum duration is 12 months (up to 18+ mos)
- SM and EMB are approximately equivalent in effect

Multiple Drugs?

- Resistance mutations occur spontaneously within a replicating population of bacteria with a predictable frequency (*f*)
  - *f* Rif-R mutation 10^{-8}; INH-R 10^{-6}
- Mutations appear independently of each other
- Among a population of 10^9 AFB (*e.g.,* Intracavitary), 10 bacteria will be Rif-resistant; 1,000 will be INH-resistant
  - These resistant populations will be mutually exclusive
  - Therefore 2 drugs will cover the entire population

Why These Drugs: Objectives of TB Therapy

- Kill actively multiplying bacteria (initial phase)
  - Improve symptoms & prevent death
  - Prevent transmission to others
  - Prevent emergence of resistance
- Sterilize disease sites (continuation phase)
  - Cure the disease
- Drugs differ in their activity against TB
  - Bactericidal
  - Bacteriostatic
  - Sterilizing

Why Do We Use These Drugs?

- Each drug has a special role in TB therapy
  - Isoniazid (H, INH): Early bactericidal activity (kill the dividing bacteria)
  - Rifampin (R, Rif): Sterilizing activity (prevents relapse)
  - Pyrazinamide (Z, PZA): Special ‘shortening’ activity
  - Ethambutol (E, EMB): Fortify the regimen to prevent drug resistance

Bacterial Targets of TB Therapy

- **Rapidly** multiplying bacteria (in cavities)
- **Slowly** multiplying bacteria (in acidic environment of macrophages or cavity wall)
- **Sporadically** multiplying bacteria (location?)

Bactericidal

- Ability of drug to rapidly kill multiplying *M. tb*
- Drugs that have early bactericidal activity reduce the chance of resistance developing
  - INH/Moxifloxacin > EMB > RIF
  - PZA is poor in this regard
- "Intensive" phase: attempting to rapidly kill multiplying bacteria
  - Smear and culture conversion

Sterilizing

- Ability of drug to kill bacilli, mainly in the subpopulations of *M. tb,* that persist beyond the early months of therapy
  - RIF (and PZA) have the greatest sterilizing activity
- "Continuation" phase: Attempting to sterilize/cure to prevent relapse

The Unique Role of PZA

- PZA does not protect against the emergence of resistance in a companion drug
- It is essential in the first 2 months to allow a short course (i.e., 6 month) regimen (BMC trials)
- PZA works best in low pH environments

Hypothetical Model of TB Chemotherapy

3 anatomic/metabolic populations of bacilli in cavitary TB



A: rapidly multiplying, INH>RIF>EMB
B: slowly multiplying, acid pH, PZA>RIF>INH
C: sporadically multiplying, RIF>INH

M. Iseman, D. Mitchison

The Ohio State University Wexner Medical Center

Preventing Complications: *Drug Selection and Dosing*

- Select individual treatment regimen based on individual risk factors for toxicity, clinical, and life conditions
  - Understand specific toxicities of TB medications
    - *e.g.,* Avoid hepatotoxic medications in patients with active hepatitis
  - Tailor regimen to accommodate lifestyle of patient
    - Case management-DOT → SAT?
- Adjust doses of specific drugs as necessary
  - Use weight-based dosing
  - Reduce doses of specific drugs if metabolism is impaired
    - *e.g.,* Increase dosing interval of EMB in renal failure (3x/wk, with dialysis)
  - Consider drug level testing/monitoring in specific circumstances
    - Malabsorption?

The Ohio State University Wexner Medical Center

Recommended Treatment Regimens

- Recommendation 3: Intensive phase
  - Daily dosing preferred
    - Strong recommendation; moderate certainty
  - May consider intermittent therapy (3x/wk)
    - Low risk for relapse
    - HIV neg
      - Conditional recommendation; low certainty
- Recommendation 4: Continuation phase
  - Daily dosing or 3x/wk
    - Strong recommendation; moderate certainty
  - Avoid 2x/wk regimens if possible
  - Avoid use of 900 INH/900 RPT 1x/wk
    - Strong recommendation; high certainty

CDC 2016

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Table 2. Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms

	Intensive Phase		Continuation Phase				
Regimen	Drug[a]	Interval and Dose[b] (Minimum Duration)	Drugs	Interval and Dose[b, c] (Minimum Duration)	Range of Total Doses	Comments[c,d]	Regimen Effectiveness
1	INH RIF PZA EMB	7 d/wk for 56 doses (8 wk), or 5 d/wk for 40 doses (8 wk)	INH RIF	7 d/wk for 126 doses (18 wk), or 5 d/wk for 90 doses (18 wk)	182–130	This is the preferred regimen for patients with newly diagnosed pulmonary tuberculosis.	Greater
2	INH RIF PZA EMB	7 d/wk for 56 doses (8 wk), or 5 d/wk for 40 doses (8 wk)	INH RIF	3 times weekly for 54 doses (18 wk)	110–94	Preferred alternative regimen in situations in which more frequent DOT during continuation phase is difficult to achieve.	
3	INH RIF PZA EMB	3 times weekly for 24 doses (8 wk)	INH RIF	3 times weekly for 54 doses (18 wk)	78	Use regimen with caution in patients with HIV and/or cavitary disease. Missed doses can lead to treatment failure, relapse, and acquired drug resistance.	
4	INH RIF PZA EMB	7 d/wk for 14 doses then twice weekly for 12 doses[e]	INH RIF	Twice weekly for 36 doses (18 wk)	62	Do not use twice-weekly regimens in HIV-infected patients or patients with smear-positive and/or cavitary disease. If doses are missed, then therapy is equivalent to once weekly, which is inferior.	Lesser

Abbreviations: DOT, directly observed therapy; EMB, ethambutol; HIV, human immunodeficiency virus; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin.

[a] Other combinations may be appropriate in certain circumstances; additional details are provided in the section "Recommended Treatment Regimens."

[b] When DOT is used, drugs may be given 5 days per week and the necessary number of doses adjusted accordingly. Although there are no studies that compare 5 with 7 daily doses, extensive experience indicates this would be an effective practice. DOT should be used when drugs are administered <7 days per week.

[c] Based on expert opinion, patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31-week) continuation phase.

[d] Pyridoxine (vitamin B6), 25–50 mg/day, is given with INH to all persons at risk of neuropathy (eg, pregnant women; breastfeeding infants; persons with HIV; patients with diabetes, alcoholism, malnutrition, or chronic renal failure; or patients with advanced age). For patients with peripheral neuropathy, experts recommend increasing pyridoxine dose to 100 mg/day.

[e] See [426]. Alternatively, some US tuberculosis control programs have administered intensive-phase regimens 5 days per week for 15 doses (3 weeks), then twice weekly for 12 doses.

Clin Infect Dis, 2016:63 (1 October) • e147

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Treatment of Culture-positive Pulmonary Tuberculosis

Preferred Regimen

2 mos - I, R, Z, E daily (56 doses, 8 wks) ***then***

4 mos - I, R daily (126 doses, 18 wks) ***or***

4 mos - I, R 3X / wk (56 doses, 18 wks)

Continuation phase increased to 7 months if initial film shows cavities and sputum is culture-positive at completion of 2 months of treatment ("Expert Opinion")

CDC 2016

Tailoring Tuberculosis Treatment Regimens

Rationale for Extending Treatment by 3 Months

- Continuation of PZA for additional 2 months does not improve outcome
- Prolongation of continuation phase by 2 months decreased relapses in silicotuberculosis from 20% to 3%

Risk Factors for Relapse: Study 22

Continuation Phase, Control (I/R Twice weekly)

Cavity	Culture Positive at 2 Mos	
	Yes	No
Yes	**21.8%**	6.2%
No	5.0%	**2.1%**

Tuberculosis Trials Consortium. Lancet. 2002; 360: 528

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Sputum Monitoring (*Simply Stated)*

- Obtain sputum every month until culture-negative for at least 2 consecutive months
- For those with *either* delayed culture conversion (beyond 2 months) *or* cavitation on plain CXR, clinicians may extend treatment to 9 months, although 6 mos is acceptable
- For those with *both* cavitation and delayed culture conversion, 9 months is recommended
- Patients with sputum cultures that remain positive at 3 months require further investigation

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Baseline Evaluations

- Collect appropriate specimens for microscopy and culture
  - 3 sputum samples, *8-24 hr apart*
  - Sputum induction or bronchoscopy
- Perform susceptibility testing for INH, Rif, EMB on an initial positive culture (each site of disease)
- Perform HIV counseling and testing for *all* patients/suspects
  - CD4, viral load if HIV-positive

Monitoring for Drug Toxicity

- At baseline
  - ALT, bilirubin, alkaline phos., serum creatinine, and platelet count
  - Eye examination (V_a, color) for all patients receiving EMB
  - Education!
- At least MONTHLY
  - Clinical evaluations usually are sufficient, *unless* abnormal baseline values are found or other risk factors for toxicity exist
    - *e.g.,* Risk factors for hepatitis: chronic hepatitis (hep. C), use of hepatotoxic drugs (including acetaminophen, EtOH, ?lipid lowering drugs), age (>35), postpartum, young black or Hispanic women
  - Eye examinations (EMB) – Monthly testing of V_a and color is recommended for patients receiving EMB >15-20 mg/kg/d and if on drug for >2 mos
- For 2nd and 3rd-line medications, seek expert consultation

CDC 2016

Response to Treatment

- May be rapid (days)
  - Signs/symptoms
- Expect > 90% sputum culture conversion by 3 months
  - If slow conversion – evaluate and consider longer treatment
- Allow return to home/work environment based on individual considerations
  - Infectiousness of case (look for clinical response, declining organisms on smear)
  - Risk of others becoming infected (contacts)

Follow-up Evaluations

- For pulmonary TB
  - Sputum smear/culture monthly until 2 consecutive samples are culture negative
    - Repeat drug susceptibility testing, other investigations, if culture-positive still at 3 months
  - If initial culture positive - consider repeat CXR at 2 mos, and get CXR at completion of therapy
  - If initial culture negative – perform 2 mos CXR to assess response; CXR at completion of therapy
- For extrapulmonary TB
  - Frequency and types of evaluations depend on site

Clinical Hepatitis in Persons Taking INH & RIF

Drug	Studies	Patients	% Clinical Hepatitis
INH	6	38,257	0.6
INH + other drugs (*NOT* Rif)	10	2,053	1.6
INH + Rif	19	6,155	2.7
Rif + other drugs (*NOT* INH)	5	1,264	1.1

Steele, *et. al*. Chest 99: 465 – 471, 1991

Serum Drug Level Monitoring

- Useful in selected circumstances
  - *e.g.,* Inadequate response to treatment, severe disease where malabsorption is questioned
- Helps determine therapeutic concentrations
  - Allows adjustments for variable drug absorptions
- Documents adherence to treatment
- May reduce toxicities

Serum Drug Level Monitoring

- Aminoglycosides
  - To reduce toxicity, achieve therapeutic levels
  - In-house (Amikacin) *vs.* send-out (Kanamycin)
- Ethambutol
  - May be useful in renal insufficiency to reduce toxicity
- Rifampin
  - To determine malabsorption (*e.g.,* In severe HIV)
- Cycloserine
  - To determine therapeutic levels

Discharge Planning

- Start when TB diagnosed or suspected:
  - Clinical/laboratory evidence or patient on TB drugs
- Pre-discharge conference:
  - Include nurse case manager, providers, discharge planners
- Home assessment by nurse case manager necessary to:
  - Prevent putting potentially vulnerable household members at-risk - especially children
  - Coordinate community follow-up for continuation and completion of therapy

Completion of Therapy

- Completion of treatment primarily defined by number of ingested doses within specified time frame (not solely on duration of therapy)
- For example:
  1. 6-month daily regimen (7 days/wk) = at least 182 doses of INH and RIF, and 56 doses of PZA
  2. 6-month daily regimen (5 days/wk) = at least 130 doses

Completion of Therapy

- In cases of drug toxicity or non-adherence to regimen, all specified number of doses must be administered within:
  - 3 months for initial phase
  - 6 months for 4-month continuation phase
- If the specified number of doses is not administered within the targeted time period, patient is considered to have interrupted therapy

Therapy Deviations

- Treatment interruptions: Significance varies with
  - Bacillary load at time of interruption
  - Time in course when interruption occurred (initial or continuation phase)
  - Duration and intermittency of interruption
- Split dosing of first line agents
  - Lowers peak serum concentrations – may encourage emergence of resistance

Treatment Interruptions in Initial Phase

- If patient has received ≥80% of total doses:
  - Consider bacillary load at time of interruption to decide if additional treatment needed (smear + or smear - ?)
- If patient has received <80% of total doses:
  - Consider duration of lapse and ability to complete full four months of Rx within 6 months time



Treatment Interruptions in Continuation Phase

- If patient received ≥80% of doses and
  - Sputum smear was negative on initial testing, further therapy may not be needed
  - Sputum smear was positive on initial test, continue therapy
- If patient received <80% of doses, and lapse is
  - <3 months long, continue therapy
  - >3 months long, restart therapy from beginning of initial phase

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER



Special Treatment Situations

- Pregnancy & breastfeeding
- Renal disease
- Indiscrete use of Fluoroquinolones

The Ohio State University
Wexner Medical Center

TB in Pregnancy

- Treatment for TB is ok
  - HRE + B_6 usual (PZA not used in US) → 9 mos reqd
  - Avoid aminoglycosides (SM, KM, AK), Capreomycin
    - May be assoc w fetal deafness
- Consider possible transplacental spread to infant
  - Prepare for examination of placenta post-delivery for pathology, AFB stains/cultures
  - Alert pediatrician to observe infant for signs of congenital TB
- Separation of mom from infant?

TB After Pregnancy

- Pediatrician evaluates baby, considers treatment (individualized) for potential transplacental contact if mother not on Rx prenatally: Review placenta data later
- Baby gets “window treatment plus” (6 months) if non-protected exposure to a case took place after delivery

Breastfeeding

- Breastfeeding ok, except in women taking fluoroquinolone
- INH given to mother is not adequate as preventive therapy in breastfeeding infant
  - Infant receives drug, may exhibit side effects
  - TB-exposed infant needs own INH, Vit B_6

Renal Disease

- Increase dosing interval of renally excreted anti-TB drugs (rather than lower dose) if Creatinine clearance decreased (<30ml/min)
  - EMB, PZA, Lqn, aminoglycosides, Capreo, CS
- Consult experts for dosing of patients on dialysis
  - No adjustment for INH & RIF
  - Lengthen interval for EMB & PZA (generally 3x/wk, following dialysis)

CDC 2016
Table 12

Treatment in Other Special Situations

- Recommendation 7: TB Pericarditis
  - Adjunctive steroids not routinely recommended
    - Conditional recommendation; very low certainty
- Recommendation 8: TB Meningitis
  - Adjunctive steroids for 6-8 weeks
    - Strong recommendation; moderate certainty
  - Use of Ethambutol as 4th drug
- Recommendation 9: Culture negative TB
  - Four months adequate
    - Conditional recommendation; very low certainty

CDC 2016

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

IDSA / ATS: Empirical Antibiotics for Community Acquired Pneumonia

- Outpatient
  - 1. Previously healthy and no use of antimicrobials within the previous 3 months
    - A macrolide (strong recommendation; level I evidence)
    - Doxycycline (weak recommendation; level III evidence)
  - 2. Presence of comorbidities such as chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; or use of antimicrobials within the previous 3 months (in which case an alternative from a different class should be selected)
    - A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg]) (strong recommendation; level I evidence)
    - A b-lactam **plus** a macrolide (strong recommendation; level I evidence)

From *Table 7:* CID. 44 (suppl. 2), 2007

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

IDSA / ATS: Empirical Antibiotics for Community Acquired Pneumonia

- Inpatients, non-ICU
  - A respiratory fluoroquinolone (strong recommendation; level I evidence)
- Inpatients, ICU
  - b-lactam + azithromycin or respiratory fluoroquinolone

From *Table 7:* CID. 44 (suppl. 2), 2007

53

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Summary

- Patient-centered case management is standard of care
- When prescribing treatment
  - Use preferred regimens
  - Extend treatment for cavitation and/or + sputum cultures at 2 mos
  - Calculate # doses within prescribed time frame
  - Use DOT as a tool to ensure treatment adherence
- Special situations
  - Be mindful of additional guidelines for pregnant or breastfeeding women, HIV (+) persons, patients with renal or liver disease

THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER



Heliotherapy (sun therapy)
Valley Echo, April, 1927

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Questions?

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

56